enGene Holdings Inc. Files 8-K Report

Ticker: ENGNW · Form: 8-K · Filed: Sep 26, 2024 · CIK: 1980845

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

enGene filed an 8-K, check for new info.

AI Summary

On September 26, 2024, enGene Holdings Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or material events beyond the filing itself were detailed in the provided text.

Why It Matters

This 8-K filing indicates that enGene Holdings Inc. is providing updated information to the SEC, which could include material disclosures relevant to investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without immediate indication of significant negative events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for enGene Holdings Inc.?

The filing serves as a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported was on September 26, 2024.

What is enGene Holdings Inc.'s principal executive office address?

The principal executive offices are located at 4868 Rue Levy, Suite 220, Saint-Laurent, Quebec, Canada, H4R 2P1.

What is enGene Holdings Inc.'s telephone number?

The company's telephone number, including area code, is 514 332-4888.

In which jurisdiction was enGene Holdings Inc. incorporated?

enGene Holdings Inc. was incorporated in British Columbia.

Filing Stats: 1,018 words · 4 min read · ~3 pages · Grade level 10.9 · Accepted 2024-09-26 06:33:37

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 26, 2024, enGene Holdings Inc. (the "Company") issued a press release announcing preliminary data from the ongoing pivotal cohort of the LEGEND study of the Company's non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70) in patients with high-risk, Bacillus Calmette-Gurin ("BCG")-unresponsive, non-muscle invasive bladder cancer ("NMIBC") with carcinoma in situ ("Cis"), a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. In addition, on September 26, 2024, the Company announced that it intends to host a conference call to discuss the preliminary data. A form of the slide presentation to be used during that conference call is being furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. The LEGEND study is a multi-cohort study to establish efficacy of detalimogene in high-risk BCG-unresponsive, NMIBC patients with Cis, as well as those with papillary-only NMIBC. The ongoing pivotal cohort is an approximately 100 patient, open-label study evaluating detalimogene in BCG-unresponsive NMIBC patients with Cis. Patients receive 800g/mL of detalimogene intravesically at weeks one, two, five, and six during a 12-week cycle, for up to four cycles, with assessments at three, six, nine, and 12 months. The study's primary efficacy endpoint is the percentage of patients with a complete response at 12 months, based on cystoscopy, urine cytology and biopsy. On September 26, 2024, the Company announced preliminary data from the ongoing pivotal cohort of the LEGEND study. As of the September 13, 2024 data cutoff date (the "data cutoff date"), 21 patients in the pivotal cohort had been assessed for response at three months, including 17 patients that had also been assessed for response at six months. Of the 21 patients, 15 were male and six were female, with a median age of 74 years (range 59-92). The patients had a median of 11 prior doses of BCG treatment (range 8-33) and their tumor stages were T1 plus Cis (three patients, 14.3%), Ta plus Cis (three patients, 14.3%) and Cis only (15 patients, 71.4%). As of the data cutoff date, 71% of patients (15 of 21) achieved a complete response ("CR") at any time, 67% of patients (14 of 21) achieved a CR at three months and 47% of patients (8 of 17) achieved a CR at six months. In the 21 patients, the complete response rate at six months was estimated using a Kaplan-Meier analysis to be 51%. Detalimogene was generally well-tolerated by patients with no discontinuations due to treatment-related adverse events ("TRAEs"). Of the 42 patients in the safety analysis, which included all patients dosed in the LEGEND Phase 2 cohorts as of the data cutoff date, 20 patients (47.6%) experienced any grade

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release dated September 26, 2024 99.2 Slide Presentation dated September 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENGENE HOLDINGS INC. Date: September 26, 2024 By: /s/ Ronald H. W. Cooper Name: Title: Ronald H. W. Cooper Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing